Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Daratumumab in combination with bortezomib and dexamethasone (DVd) has demonstrated longer progression-free survival than combination of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). In this multicenter, open-label, phase-1 study, the safety, efficacy, and pharmacokinetics (PK) of DVd were evaluated in Japanese patients with RRMM. Eight patients with RRMM aged between 54 and 82 years were enrolled and treated with DVd regimen. Primary endpoints were tolerability and safety. Secondary endpoints were overall response rate (ORR), very good partial response (VGPR) or better, complete response (CR) or better, time to response (TTR), PK, and immunogenicity. All patients (n = 8) experienced Grade ≥ 3 treatment-emergent adverse events (TEAE), with thrombocytopenia (n = 6, 75%) being the most frequent. Mild Grade ≤ 2 infusion-related reactions were reported in five patients. Serious TEAEs were herpes zoster, nasopharyngitis, and prostate cancer (n = 1 each). Three dose-limiting toxicities were observed in two patients. No death or disease progression was reported as of the study cut-off date. ORR was 100% (2 CRs or better, 2 VGPRs, 4 PRs). The median TTR was 0.9 months. PK profiles were comparable to previous studies. The DVd regimen showed acceptable safety with favorable efficacy in Japanese patients with RRMM.

Clinical trial registration number

NCT02497378.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Raedler LA. Darzalex (Daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefit. 2016;9(Spec Feature):70–3.

    Google Scholar 

  2. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5:e349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

    Article  CAS  PubMed  Google Scholar 

  4. Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.

    Article  CAS  PubMed  Google Scholar 

  6. Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279–87.

    Article  CAS  PubMed  Google Scholar 

  7. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8.

    Article  CAS  PubMed  Google Scholar 

  8. Kumar N, Zaw AS, Reyes MR, Malhotra R, Wu PH, Makandura MC, et al. Versatility of percutaneous pedicular screw fixation in metastatic spine tumor surgery: a prospective analysis. Ann Surg Oncol. 2015;22:1604–11.

    Article  PubMed  Google Scholar 

  9. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7:97–111.

    Article  CAS  PubMed  Google Scholar 

  10. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–60.

    Article  CAS  PubMed  Google Scholar 

  12. Approved drugs—daratumumab (DARZALEX). https://www.fda.gov/Drugs/informationOnDrugs/ApprovedDrugs/ucm530249.htm. Accessed 17 May 2017.

  13. Janssen Biotech Inc. DarzalexTM (daratumumab): prescribing information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf. Accessed 17 May 2017.

  14. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    Article  CAS  PubMed  Google Scholar 

  15. Iida S, Suzuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, et al. Safety and efficacy of daratumumab in japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. Int J Hematol. 2017;106:541–51.

    Article  CAS  PubMed  Google Scholar 

  16. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  CAS  PubMed  Google Scholar 

  17. Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–8.

    Google Scholar 

  19. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29:587–90.

    Article  CAS  PubMed  Google Scholar 

  20. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, et al. Retrospective matched-pair analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015;100:100–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi133–7.

    PubMed  Google Scholar 

  22. Mateos M-V, Moreau P, Comenzo R, Bladé J, Benboubker L, de La Rubia J, et al. An open-label, multicenter, phase 1B study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. European Hematology Association; 2015. Abstract p. 275.

  23. Endell J, Samuelsson C, Boxhammer R, Strauss S, Steidl S. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. J Clin Oncol. 2011;29: 2011 (suppl; abstr 8078) suppl; abstr 8078. http://meetinglibrary.asco.org/content/80499-102. Accessed 17 May 2017.

  24. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1:e41.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–19.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was sponsored by Janssen Research & Development, LLC.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Shinsuke Iida

  2. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Tatsuo Ichinohe

  3. Hitachi General Hospital, Hitachi, Japan

    Atsushi Shinagawa

  4. Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

    Kenshi Suzuki

  5. Department of Hematology, National Disaster Medical Center of Japan, Tokyo, Japan

    Naoki Takezako

  6. Janssen Pharmaceutical K.K., Tokyo, Japan

    Masayuki Aoki

Authors
  1. Shinsuke Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuo Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Shinagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Takezako
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayuki Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. Aoki had primary role in the study design, analysis and data interpretation. Drs Iida, Ichinohe, Shinagawa, Suzuki and Takezako were involved in study design, data interpretation and also involved as investigators. All authors contributed to the development of the manuscript and approved the final manuscript for submission. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Corresponding author

Correspondence to Shinsuke Iida.

Additional information

Previous publication: The abstract submitted to the JSH, 20–22th October, 2017 in Yokohama, Japan.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 16 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iida, S., Ichinohe, T., Shinagawa, A. et al. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol 107, 460–467 (2018). https://doi.org/10.1007/s12185-017-2390-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2390-2

Keywords

Search

Navigation